No Longer Lost in the Blink of an Eye
It’s a problem as old and as aggravating as eye drops themselves: as soon as the medicine goes in, almost all of it washes right back out again.
Now, McMaster chemical engineer Heather Sheardown and the graduate students in her lab have developed a better way to deliver medicine to the surface of the eye.
They have created microscopic packets of medicine that lodge themselves imperceptibly in the base of the tear film that makes up the wet surface of the eye.
There, the molecular packets, or depots, dissolve gradually, releasing medicine slowly and making it possible for people with conditions such as dry eye and glaucoma – which require daily drops – to receive the same degree of treatment from using drops just once a week.
Sheardown, a Canada Research Chair in Ophthalmic Biomaterials and Scientific Director of the 20/20 NSERC Ophthalmic Materials Research Network, says that partners in the field had named the problem with conventional eye drops as one of the top issues in all of eye care.
The problem is that the eye does a good job of defending itself against foreign substances, making it difficult for the active ingredients in eye drops to do their work before the eye sheds them.
With conventional drops, 95 per cent of the medicine is typically lost before it has a chance to work, a frustrating inefficiency, especially for patients.
“It’s a lousy delivery system,” Sheardown says. “If you can deliver drops to the front of the eye at lower concentrations that work over a longer period, it could be huge.”
Sheardown’s team is in the final stages of proving the safety and effectiveness of the new technology, which was described recently in the journal Biomacromolecules. The research was funded by the 20/20 NSERC Ophthalmic Materials Research Network and The Boris Family Foundation.
Sheardown is presenting the new technology to the Tear Film and Ocular Surface Society in France in September.
She says there has been interest in commercializing the technology, and she hopes it will be on the market in the near future.
Learn more: NO LONGER LOST IN THE BLINK OF AN EYE
The Latest on: Eye drop drug delivery
via Google News
The Latest on: Eye drop drug delivery
- Two biotechs target dry eye disease after Novartis’ Xiidra problemson March 3, 2021 at 7:55 pm
The pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, aiming to disrupt a market led by Allergan and Novartis.
- Tired of reading glasses? Eye drop submitted for FDA approval may help you read without them.on March 2, 2021 at 3:19 am
A new drug that could help more than 128 million Americans with presbyopia has been submitted to the Food and Drug Administration for approval.
- World Ophthalmic Drugs Market Size, Share & Trends Analysis 2021-2028: Focus on Dry Eye, Eye Allergy, Glaucoma, Eye Infectionon February 23, 2021 at 5:36 am
The "Ophthalmic Drugs Market Size, Share & Trends Analysis Report by Disease (Dry Eye, Eye Allergy, Glaucoma, Eye Infection), by Drug Class, by Dosage Form, by Route Of Administration, by Product Type ...
- Ophthalmic Drugs Market Size, Share & Trends Analysis Report 2021-2028: Strong Developmental Pipeline, Advancements In Drug Delivery, Promising Investon February 22, 2021 at 12:16 pm
The "Ophthalmic Drugs Market Size, Share & Trends Analysis Report by Disease (Dry Eye, Eye Allergy, Glaucoma, Eye Infection), by Drug Class, by Dosage Form, by Route Of Administration, by Product Type ...
- Ophthalmic Drug Market Size Worth $60.3 Billion By 2028 | CAGR: 6.4%: Grand View Research, Inc.on February 15, 2021 at 1:40 am
An increase in the prevalence of eye-related disorders ... solutions and suspensions in the near future and its direct drug delivery mechanism North America dominated the market and accounted ...
- Missouri graduate to share in invention profits under dealon February 3, 2021 at 11:46 am
A Missouri graduate who said his professor stole his invention for a drug delivery system will ... of nanotechnology that delivers drops to the back of the eye. It is one of the leading treatments ...
- Missouri Graduate to Share in Invention Profits Under Dealon February 3, 2021 at 11:04 am
Before the settlement, Cholkar had stood to collect nothing from his invention of nanotechnology that delivers drops to the back of the eye ... Ashim Mitra; the drug development company, Auven ...
- Missouri graduate to share in invention profits under dealon February 3, 2021 at 11:03 am
(AP) — A Missouri graduate who said his professor stole his invention for a drug delivery system will share in ... from his invention of nanotechnology that delivers drops to the back of the eye. It ...
- Théa inks $135M deal for EU rights to Nevakar's myopia eye dropson February 2, 2021 at 3:37 pm
Laboratoires Théa has secured the European rights to the low-dose atropine eye drop NVK-002 from Nevakar in a deal worth up to $135 million. Nevakar is developing the candidate as a treatment for ...
via Bing News